Pfizer's Trumenba meets in two Phase III trials

Pfizer Inc. (NYSE:PFE) said meningitis B vaccine Trumenba met its primary endpoints in two Phase III trials. FDA had granted accelerated approval to Trumenba in October 2014 to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals aged 10-25.

Spokesperson Sally Beatty declined to disclose when Pfizer will submit the Phase III results to FDA. ...